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Caffeic acid phenethyl ester
vitamin E TPGS
Nanomedicine
Drug delivery systema b s t r a c t
CAPE found in propolis has become the subject of research interest as it has various medicinal benefits
such as antiviral, anti-inflammatory, antioxidant, anticancer and immunomodulatory properties [1]. In
this study, propolis obtained in Kuantan, Pahang is encapsulated using biodegradable polymer, vitamin
E TPGS as a drug delivery system whereas TPGS-CAPE is used as a control. The findings show the physical
characterization of propolis loaded vitamin E TPGS polymeric micelles which includes size, polydispersity
index, zeta potential, shape and morphology and encapsulation efficiency.
 2021 Elsevier Ltd. All rights reserved.
Selection and peer-review under responsibility of the scientific committee of the 2nd International Con-
ference on Innovative Technology and Sciences (iCITES 2020).1. Introduction
Propolis is a complex mixture that synthesized by honeybee
from resin of a plant to build the hive and to keep moisture and
temperature stable in the hive. The composition of propolis is var-
ied by its botanical and geographical origin as well. Basically, raw
propolis is mainly composed of plant resins (50–70%), oil and
waxes (30–50%), 10% pollen essential (5%-10%) and other chemical
compounds including amino acids, minerals, sugars, vitamin B, C
and E, flavonoids, phenol and aromatic compound [2].
Since thousands years ago, ancient civilization utilized propolis
for its versatile medicinal properties. For example, Egyptians used
propolis which contains bee wax as material for mummification
process [3]. Besides, Assyrian put propolis on wound and tumour
to fight against bacterial infection and facilitate the healing pro-
cess. In ancient Greece, propolis was also used to produce polyan-
thus perfume. Polyanthus is a kind of flower that emanates
fragrance smell. According to Kuropatnicki et al., Greeks introduced
propolis as primary ingredient to mix with other materials such as
olibanum, styrax, and aromatic herbs [4]. Nowadays, propolis has
become the interest of study by researchers and chemist as more
than 300 compounds has been identified in propolis such as phe-
nolic compounds that include flavonoids, phenolic acid, tannins,
quinines, stilbenes, coumarins and curcuminoids [2]. Hence, thesebioactive compounds in propolis contribute many properties that
are essential for pharmaceutical development. For instances, it
has antibacterial, antifungal, antioxidants, anti-inflammatory,
antidiabetic and antitumoral properties.
In this study, the target phenolic compound in propolis is caffeic
acid phenethyl ester (CAPE). CAPE is one of the derivatives of caf-
feic acid. It is a hydrophobic, bioactive polyphenolic ester of propo-
lis produced by honey bees and plants as well. Murtaza et al.
emphasizes the biological and pharmacological activities of CAPE
such as antimicrobial, anti-inflammatory, anticancer activities
and diminishing chemotherapy-induced toxicities [1]. Further-
more, Indian stingless bee propolis was reported to have a potent
anticancer activity on cell lines such as human breast adenocarci-
noma (MCF-7), human colon adenocarcinoma (HT-29), human
epithelial colorectal adenocarcinoma (Caco-2), and murine mela-
noma cell lines (B16F1). The propolis causes cell death due to
induction of apoptosis [5].
Preparation of propolis into nanomedicine as targeted drug
delivery system able to deliver the pharmacological active compo-
nents to specific tissues. Nanocarriers help to improve drug prop-
erties by encapsulating hydrophilic or hydrophobic molecules in
their core, hence controlling release and distribution, enhancing
drug absorption by cells and protecting the drug from degradation
before reaching the targeted site [6]. In this study, d-a-Tocopheryl
polyethylene glycol 1000 succinate (TPGS), also known as vitamin
E TPGS is water soluble form of vitamin E. It possesses amphipathic
properties is chosen as the nanocarrier to improve the solubility of0).
aterials
Table 1
The condition for the gradient elution of CAPE.
Time (min) Flow (mL/min) A (%) B (%) C (%) D (%)
0 0.5 90 10 0 0
1 0.5 90 10 0 0
10 0.5 80 20 0 0
20 0.5 70 30 0 0
30 0.5 50 50 0 0
40 0.5 10 90 0 0
45 0.5 90 10 0 0
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and CAPE is hydrophobic in nature. Biodegradable nanocarrier is
also one of the major concerns in pharmaceutical application as
polymers is safe and it can be eliminated through natural pathways
either by simple filtration of degradation by-products or metabo-
lized products in body system.
Owning to its versatile medicinal properties, propolis has
potential therapeutic in different diseases. It can be prepared into
nanomedicine for targeted treatment and this also helps to
improve bioavailability of the active components in propolis due
to its water solubility issue.
2. Material and methods
2.1. Materials
Raw propolis was obtained from Q’Lulut Global in Kuantan,
Malaysia. Caffeic acid phenethyl ester (CAPE), vitamin E TPGS,
phosphate buffered saline (PBS) were all purchased from Sigma
Aldrich whereas acetonitrile was purchased from Thermo Fisher.
2.2. Raw material preparation
Raw propolis was directly collected from hives of stingless bees
(Trigona thoracica) in Q’lulut Global, Kuantan, Malaysia. Raw pro-
polis was grounded into fine powder and kept in 80 C freezer
using for long-term storage.
2.3. Extraction of propolis
Propolis was extracted using 70% ethanol by maceration
method [11]. The ratio of solvent and propolis was 10:1 (v/w).
Firstly, 10 g of propolis was mixed vigorously with 100 mL of
70% ethanol for 3 min at room temperature, 25 C. The mixture
was left overnight at room temperature in the incubator shaker
(Infors HT Ecotron, Switzerland) with rotation speed of 120 rpm
for 24 h. Next, the suspension was filtered through Whatman No.
1 filter paper. The filtrate was then concentrated using a rotary
evaporator at 40 C with rotation speed of 120 rpm to eliminate
the solvent. The concentrate was stored under 80 C before freeze
drying using VirTis Benchtop Pro freeze dryer (SP Scientific, New
York, United States).
2.4. Preparation of TPGS-propolis micelles and CAPE micelles
TPGS-propolis micelles were prepared according to the solvent
casting method [8]. A total of 3 mg of propolis and 50 mg of vita-
min E TPGS were dissolved in 3 mL of chloroform. From this mix-
ture, chloroform was evaporated using rotary evaporator at 40 C
and a thin film of drug dispersed TPGS was formed. The thin film
was subjected to freeze drying for 2 h. Then, drug-loaded micelles
was formed by resuspending the drug-loaded film in 1 mM PBS at
pH 7.4. The mixture was incubated in incubator shaker at 37 C for
48 h. The samples were centrifuged at 25000 rpm for 20 min to
sediment the micelles for further characterization. All the steps
was repeated to prepare CAPE micelles where 3 mg of propolis
was replaced by 3 mg of CAPE.
2.5. Particle Size, polydispersity and zeta potential
The average particle size, zeta potential and polydispersity
index (PDI) of the formulation was measured by dynamic light
scattering analysis by photon correlation spectroscopy (Zetasizer
Nano ZS, UK). Data are representative of at least three independent
experiments.2
2.6. Surface morphology
The shape and surface morphology of the micelles were visual-
ized using transmission electron microscope (TEM). Samples were
prepared by placing one drop of micelles solution on a copper grid
and then dried under vacuum pressure.2.7. Encapsulation efficiency
The encapsulation efficiency (EE) was determined by measuring
the amount of free CAPE present in the formulation. The amount ofCAPE in the formulations was determined by HPLC method
(Agilent HPLC 1260 series, USA). Chromatographic separation
was performed using an Eclipse Plus C18 column (250 mm  4.6
mm, 5 lm) (Agilent, United State) by isocratic elution. The temper-
ature of column was set at 35 C and the injection volume was
1 lL. The mobile phases consist of ultra-purified water (A) and
95% acetonitrile (B) which were prepared respectively. Cleaning
agent C and D are 20% acetonitrile and 100% acetonitrile respec-
tively. Before the HPLC analysis, the mobile phase was filtered
through a 0.45 lm membrane filter and samples were filtered
through 0.2 lm polyethersulfone (PES) membrane filter. After that,
mobile phase was sonicated for 30 min to degas before the HPLC
analysis. The flow rate was set at 0.5 mL/min and the effluent
was monitored using a DAD set at 245 nm for CAPE quantification.
As shown in Table 1, a gradient elution mode is used for the anal-
ysis of CAPE. This is because the presence of related compounds,
such as other caffeic acid esters have a close polarity, hence it does
not allow for efficient determination of this component in the iso-
cratic elution mode [7]. The amount of encapsulated propolis was
calculated with the formula given below.
Encapsulationefficiency %ð Þ ¼ TotalamountofCAPEinformualtion  freeCAPE
TotalamountofCAPEusedinformulation
 100%
2.8. Standard solution preparation and sample preparation
The stock solution was prepared by dissolving 32 mg of CAPE in
10 mL acetonitrile. Then, 200, 400, 800, 1600 and 3200 lg/mL of
standard solution of CAPE were diluted from the stock solution
by using mobile phase. For sample preparation, 0.1 g of propolis
extracts in 10 mL of mobile phase. However, 2 mL of TPGS-
propolis micelles and 2 mL of TPGS-CAPE micelles were freeze
dried and then dissolved in 2 mL of mobile phase respectively.
All the standard solution of CAPE and micelles samples were fil-
tered through 0.2 lm PES membrane filter.3. Results and discussion
3.1. Particle size, polydispersity index and zeta potential
The particle size, PDI and zeta potential of the micelles are
measured by dynamic light scattering (DLS) analysis by photon
Table 2
Particle size, polydispersity index, zeta potential and encapsulation efficiency of TPGS-propolis and TPGS-CAPE micelles.
Micelles Size (nm) Polydispersity index (PDI) Zeta Potential (mV) Encapsulation efficiency (%)
TPGS-propolis 13.68 ± 0.13 0.24 ± 0.02 11.83 ± 1.56 97.19
TPGS-CAPE 15.56 ± 0.07 0.29 ± 0.05 13.73 ± 0.84 95.03
Fig. 1. Representative TEM images a) TPGS-propolis micelles; b) TPGS-CAPE
micelles.
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TPGS-propolis and TPGS-CAPE micelles are distributed from
10 nm to 20 nm. This result can also be observed from TEM images
as show in Fig. 1. The polydispersity index of all the micelles is less
than 0.3 which indicates a narrow size distribution. It has been
reported that typical micelles size is in the range of 10 nm to
100 nm which are suitable for drug delivery in cancer therapy
[8]. These results are tallied with the docetaxel-loaded vitamin E
TPGS micelles prepared by Muthu et al. [10].
Zeta potential indicates the surface charge of the nanoparticles
which directly deals with the stability of the colloidal dispersion
through electrostatic repulsion between the particles. Higher zeta
potential able to prevents aggregation of the nanoparticles due to
the Van der Walls force attraction between the nanoparticles.
Zeta potential for both of the micelles maintains between
10 mV to 15 mV. The negative surface charge is caused by
the presence of carboxyl end group located near the surface
where the oxygen atom develops a partial negative charge (d-)
[9]. Besides, use of surfactant such as TPGS further reduces the
surface charge. However, aggregation of nanoparticles can be pre-
vented despite of lower value of zeta potential by the hydrophilic
PEG chains of TPGS [9].3
3.2. Surface morphology
Transmission electron microscope (TEM) was used to reveal the
surface morphology of the micelles. As shown in Fig. 1., the
micelles were discrete, having a smooth surface and are spherical
in shape. The particle size obtained in TEM image is well correlated
with the measurement done by photon correlation spectroscopy.
3.3. Encapsulation efficiency
In nanoparticle drug delivery system, the encapsulation effi-
ciency is defined as the drug carrying capacity. Both of the samples
had an encapsulation efficiency of 90% and above. For TPGS-
propolis micelles, drug encapsulation efficiency was determined
by CAPE present in the propolis extracts and micelles. The reten-
tion time of standard CAPE is 36.3 min.
4. Conclusion
This study shows the physical characterization of TPGS-propolis
micelles as nanomedicine and its particle size is suitable to be used
in targeted cancer treatment and other diseases. Encapsulate
hydrophobic active component in nanocarrier can greatly improve
water solubility of propolis. Hydrophilic surface possessed by TPGS
micelles allows hydrophobic propolis to escape from reticuloen-
dothelial system, therefore the micelles have a longer half-life in
the systemic circulation [10].
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